Analysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal Liposarcoma

Sarcoma

Volumn 2015, Issue , 2015, Pages

  Tseng, William W ^a,b   Malu, Shruti ^c   Zhang, Minying ^c   Chen, Jieqing ^c   Sim, Geok Choo ^c   Wei, Wei ^c   Ingram, Davis ^c   Somaiah, Neeta ^c   Lev, Dina C ^c   Pollock, Raphael E ^d   Lizée, Gregory ^c   Radvanyi, Laszlo ^e,f   Hwu, Patrick ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e Lion Biotechnologies   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84935037781     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2015/547460     Document Type: Conference Paper

References (34)

1. M. A. Clark, C. Fisher, I. Judson, and J. M. Thomas, "Soft-tissue sarcomas in adults, " The New England Journal of Medicine, vol. 353, no. 7, pp. 701-711, 2005.
2. J.-M. Coindre, F. Pédeutour, and A. Aurias, "Well-differentiated and dedifferentiated liposarcomas, " Virchows Archiv, vol. 456, no. 2, pp. 167-179, 2010.
3. L. G. Dodd, "Update on liposarcoma: a review for cytopathologists, " Diagnostic Cytopathology, vol. 40, no. 12, pp. 1122-1131, 2012.
4. W. W. Tseng, B. W. Feig, D. C. Lev, and R. E. Pollock, "Surgery: chronic, primary treatment for well differentiated liposarcoma and a critical component of aggressive, multimodality treatment for dedifferentiated liposarcoma, " in Treatment Strategies-Oncology, Cambridge Research Centre, London, UK, 2012.
5. A. Hoffman, A. J. Lazar, R. E. Pollock, and D. Lev, "Newfrontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort, " Drug Resistance Updates, vol. 14, no. 1, pp. 52-66, 2011.
6. A. Italiano, M. Toulmonde, A. Cioffi et al. , "Advanced welldifferentiated/ dedifferentiated liposarcomas: role of chemotherapy and survival, " Annals of Oncology, vol. 23, no. 6, pp. 1601-1607, 2012.
7. W. W. Tseng, N. Somaiah, A. J. Lazar, D. C. Lev, and R. E. Pollock, "Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results, " Cancers, vol. 5, no. 2, pp. 529-549, 2013.
8. I. Ray-Coquard, J.-Y. Blay, A. Italiano et al. , "Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanismstudy, "TheLancet Oncology, vol. 13, no. 11, pp. 1133-1140, 2012.
9. M. A. Dickson, W. D. Tap, M. L. Keohan et al. , "Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma, " Journal of Clinical Oncology, vol. 31, pp. 2024-2028, 2013.
10. F. S. Hodi, S. J. O'Day, D. F. McDermott et al. , "Improved survival with ipilimumab in patients with metastatic melanoma, " TheNewEngland Journal ofMedicine, vol. 363, pp. 711-723, 2010.
11. C. Robert, L. Thomas, I. Bondarenko et al. , "Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, " The New England Journal ofMedicine, vol. 364, no. 26, pp. 2517-2526, 2011.
12. J. D. Wolchok, H. Kluger, M. K. Callahan et al. , "Nivolumab plus Ipilimumab in advanced melanoma, "The New England Journal of Medicine, vol. 369, no. 2, pp. 122-133, 2013.
13. O. Hamid, C. Robert, A. Daud et al. , "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, "TheNew England Journal of Medicine, vol. 369, no. 2, pp. 134-144, 2013.
14. L. Calabrò, A. Morra, E. Fonsatti et al. , "Tremelimumab for patients with chemotherapy-resistant advanced malignantmesothelioma: an open-label, single-arm, phase 2 trial, " The Lancet Oncology, vol. 14, no. 11, pp. 1104-1111, 2013.
15. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al. , "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, " The New England Journal of Medicine, vol. 366, no. 26, pp. 2443-2454, 2012.
16. S. M. Pollack, A. A. Jungbluth, B. L. Hoch et al. , "NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma, " Cancer, vol. 118, no. 18, pp. 4564-4570, 2012.
17. M. E. Dudley, J. R. Wunderlich, T. E. Shelton, J. Even, and S. A. Rosenberg, "Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients, " Journal of Immunotherapy, vol. 26, no. 4, pp. 332-342, 2003.
18. L. G. Radvanyi, C. Bernatchez, M. Zhang et al. , "Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients, " Clinical Cancer Research, vol. 18, no. 24, pp. 6758-6770, 2012.
19. W. W. Tseng, E. G. Demicco, A. J. Lazar, D. C. Lev, and R. E. Pollock, "Lymphocyte composition and distribution in inflammatory, well-differentiated retroperitoneal liposarcoma: clues to a potential adaptive immune response and therapeutic implications, " The American Journal of Surgical Pathology, vol. 36, no. 6, pp. 941-944, 2012.
20. P. Argani, F. Facchetti, G. Inghirami, and J. Rosai, "Lymphocyterich well-differentiated liposarcoma: report of nine cases, " The American Journal of Surgical Pathology, vol. 21, no. 8, pp. 884-895, 1997.
21. M. D. Kraus, L. Guillou, and C. D. M. Fletcher, "Well-differentiated inflammatory liposarcoma: an uncommon and easily overlooked variant of a common sarcoma, " The American Journal of Surgical Pathology, vol. 21, no. 5, pp. 518-527, 1997.
22. T. Peng, P. Zhang, J. Liu et al. , "An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors, " Laboratory Investigation, vol. 91, no. 3, pp. 392-403, 2011.
23. Z. Wang, L. Yang, Y. Jiang et al. , "High fat diet induces formation of spontaneous liposarcoma in mouse adipose tissue with overexpression of interleukin 22, " PLoS ONE, vol. 6, no. 8, Article ID e23737, 2011.
24. A. Gros, P. F. Robbins, X. Yao et al. , "PD-1 identifies the patientspecific CD8+ tumor-reactive repertoire infiltrating human tumors, "The Journal of Clinical Investigation, vol. 124, no. 5, pp. 2246-2259, 2014.
25. J. R. Kim, Y. J. Moon, K. S. Kwon et al. , "Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas, " PLoS ONE, vol. 8, no. 12, Article ID e82870, 2013.
26. M.-C. Dieu-Nosjean, M. Antoine, C. Danel et al. , "Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures, " Journal of ClinicalOncology, vol. 26, no. 27, pp. 4410-4417, 2008.
27. D. Coppola, M. Nebozhyn, F. Khalil et al. , "Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling, " The American Journal of Pathology, vol. 179, no. 1, pp. 37-45, 2011.
28. J. L. Messina, D. A. Fenstermacher, S. Eschrich et al. , "12-chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?" Scientific Reports, vol. 2, article 765, 2012.
29. J. Barretina, B. S. Taylor, S. Banerji et al. , "Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy, " Nature Genetics, vol. 42, no. 8, pp. 715-721, 2010.
30. B. S. Taylor, P. L. DeCarolis, C. V. Angeles et al. , "Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas, " Cancer Discovery, vol. 1, no. 7, pp. 587-597, 2011.
31. R.-R. Ji, S. D. Chasalow, L. Wang et al. , "An immune-active tumor microenvironment favors clinical response to ipilimumab, " Cancer Immunology, Immunotherapy, vol. 61, no. 7, pp. 1019-1031, 2012.
32. J. M. Taube, R. A. Anders, G. D. Young et al. , "Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, " Science Translational Medicine, vol. 4, no. 127, Article ID 127ra37, 2012.
33. S. P. D'Angelo, W. D. Tap, G. K. Schwartz, and R. D. Carvajal, "Sarcoma immunotherapy: past approaches and future directions, " Sarcoma, vol. 2014, Article ID 391967, 13 pages, 2014.
34. W. W. Tseng, N. Somaiah, and E. G. Engleman, "Potential for immunotherapy in soft tissue sarcoma, " Human Vaccines & Immunotherapeutics. In press.